ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
120.771,88
0,00%
S&P 500
5.872,16
-2,95%
US Dollar vs BRL
6,2746
-0,25%
Bitcoin
101.969,64
1,91%
Brent Oil
72,86
0,17%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Mesoblast Limited (MESO)

  7. Mesoblast Limited (MESO) Notícias

MESO

Mesoblast (MESO)

Mesoblast Limited
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:MESO
DataHoraFonteTítuloCódigoCompanhia
18/12/202421:08GlobeNewswire Inc.Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) TherapyNASDAQ:MESOMesoblast Limited
18/12/202409:30GlobeNewswire Inc.Mesoblast to be Added to Nasdaq Biotechnology IndexNASDAQ:MESOMesoblast Limited
13/12/202418:04Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:MESOMesoblast Limited
09/12/202418:21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
04/12/202420:32GlobeNewswire Inc.FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
02/12/202420:20GlobeNewswire Inc.Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With InflammationNASDAQ:MESOMesoblast Limited
30/10/202420:11GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024NASDAQ:MESOMesoblast Limited
09/10/202416:42Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MESOMesoblast Limited
29/09/202421:55GlobeNewswire Inc.Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product LaunchNASDAQ:MESOMesoblast Limited
28/08/202420:27GlobeNewswire Inc.Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024NASDAQ:MESOMesoblast Limited
27/08/202420:25GlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
30/07/202422:13GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024NASDAQ:MESOMesoblast Limited
23/07/202408:53GlobeNewswire Inc.FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)NASDAQ:MESOMesoblast Limited
21/07/202421:45GlobeNewswire Inc.Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back PainNASDAQ:MESOMesoblast Limited
08/07/202421:37GlobeNewswire Inc.Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)NASDAQ:MESOMesoblast Limited
01/07/202402:55GlobeNewswire Inc.Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next WeekNASDAQ:MESOMesoblast Limited
02/06/202421:23GlobeNewswire Inc.Mesoblast Corporate Presentation at Investor ConferenceNASDAQ:MESOMesoblast Limited
29/04/202422:05GlobeNewswire Inc.Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024NASDAQ:MESOMesoblast Limited
26/03/202410:25AllPennyStocks.comFDA Commentary Sends Biotech Soaring During Premarket HoursNASDAQ:MESOMesoblast Limited
25/03/202423:34GlobeNewswire Inc.United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)NASDAQ:MESOMesoblast Limited
13/03/202420:30GlobeNewswire Inc.Mesoblast Successfully Completes Placement and Accelerated Entitlement OfferNASDAQ:MESOMesoblast Limited
10/03/202420:54GlobeNewswire Inc.United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)NASDAQ:MESOMesoblast Limited
28/02/202419:57GlobeNewswire Inc.Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023NASDAQ:MESOMesoblast Limited
14/02/202421:46GlobeNewswire Inc.United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
30/01/202423:13GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023NASDAQ:MESOMesoblast Limited
18/01/202421:28Dow Jones NewsMesoblast Gets FDA's Special Pediatric Designation for Revascor Heart TreatmentNASDAQ:MESOMesoblast Limited
18/01/202420:36GlobeNewswire Inc.United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
04/01/202423:57Edgar (US Regulatory)Form F-6 POS - Post-effective amendments for immediately effective filingNASDAQ:MESOMesoblast Limited
26/11/202320:56GlobeNewswire Inc.Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
22/11/202315:35AllPennyStocks.comBiotech Shares Soar Following Major AnnouncementNASDAQ:MESOMesoblast Limited
 Apresentando as notícias mais relevantes sobre:NASDAQ:MESO

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
ATOM3
ATOMPAR ON
BOV
COGN3
COGNA ON
BOV
AZUL4
AZUL PN
BOV
AMOB3
Automob Participacoes ON
BOV
CVCB3
CVC BRASIL ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
IDIV
Dividend
BOV
PRIO3
PETRORIO ON
BOV
BAZA3
AMAZONIA ON
BOV
BRAV3
Brava Energia ON
BOV
BRFS3
BRF S/A ON
BOV
GPIV33
Gp Investments
BOV
HBRE3
HBR Realty Empreendiment... ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados